Agnieszka Skoczylas

Agnieszka Skoczylas

Auto-generated profile, based on publicly available information

Agnieszka Skoczylas

Department of Geriatrics, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ERElzbieta Radzikowska
Elzbieta Radzikowska
EWElżbieta Wiatr
Elżbieta Wiatr
RLRenata Langfort
Renata Langfort
IBIwona Bestry
Iwona Bestry
ASAgnieszka Skoczylas
Agnieszka Skoczylas
KRKazimierz Roszkowski-Śliż
Kazimierz Roszkowski-Śliż
Cryptogenic organizing pneumonia (COP) is a clinicopathological syndrome of unknown origin. Corticosteroids are the standard treatment, but clarithromycin (CAM) is also effective. The aim of this observational retrospective study was to compare the results of CAM versus prednisone (PRE) treatment in patients with biopsy-proven OP without respiratory insufficiency. In a 15-year period, 40 patients were treated with CAM (500 mg twice daily orally for 3 months) and 22 with PRE (mean initial dose of 0.67 ± 0.24 mg/kg/d for a mean of 8.59 ± 3.05 months). The clinical presentation, laboratory, and radiological findings did not differ markedly between patients treated with CAM and PRE, with the exception of a higher frequency of sweats (55% vs. 23%; p < 0.015), ground glass opacities (95% vs. 50%; p <0.0001) and nodular lesions (45% vs. 18%; p = 0.036) in the CAM group. A complete response was achieved in 35(88%) patients treated with CAM and in all treated with PRE. Patients treated with PRE relapsed more frequently than those treated with CAM (54.5% vs. 10%; p < 0.0001). Corticosteroid-related adverse events were noticed in 8(6.5%) patients (with one death), but CAM caused only one (2.5%) allergic reaction. A FVC >80% identified patients who might be successfully treated with CAM with a sensitivity of 60% and a specificity of 88.57% (AUC 0.869; 95% CI 0.684–1; p = 0.008); the figures for the FEV1 were >70%, a sensitivity of 60%, and a specificity of 91.43% (AUC 0.809; 95%CI 0.609–1; p = 0.027). CAM can be used to treat COP patients in whom the pulmonary function parameters are within normal limits. Such therapy is shorter, better tolerated, and associated with fewer adverse events and relapses than is PRE. However, the therapy is ineffective in some patients.

6 September 2018 in Journal of Ultrasonography
Verified
Journal Article
Open access
Natalia BudaNatalia Buda
Natalia Buda
WKWojciech Kosiak
Wojciech Kosiak
ERElżbieta Radzikowska
Elżbieta Radzikowska
RORobert Olszewski
Robert Olszewski
EJEwa Jassem
Ewa Jassem
AZAnna Zamojska
Anna Zamojska
Polish recommendations for lung ultrasound in internal medicine (POLLUS-IM)

23 March 2020 in Lung
Verified
Journal Article
Open access
PDF file
MSMałgorzata Sobiecka
Małgorzata Sobiecka
KLKatarzyna Lewandowska
Katarzyna Lewandowska
JKJarosław Kober
Jarosław Kober
MFMonika Franczuk
Monika Franczuk
ASAgnieszka Skoczylas
Agnieszka Skoczylas
MSMonika Szturmowicz
Monika Szturmowicz
Introduction: Pulmonary hypertension (PH) is a well-recognised complication of interstitial lung diseases (ILD), which worsens prognosis and impairs exercise capacity. Echocardiography is the most widely used, non-invasive method for PH assessment. The aim of our study was to identify the factors predictive for echocardiographic signs of PH in newly recognised ILD patients. Methods: Ninety-three consecutive patients (28F/65M) with different ILD were prospectively evaluated from January 2009 to March 2014. Pulmonary function testing, 6-min walk distance (6MWD), initial and sixth minute room air oxygen saturation, NT-proBNP and echocardiography were assessed in each patient. Echocardiographic PH probability was determined according to the 2009 ESC/ERS guidelines. Results: In 41 patients (Group B) increased PH possibility has been diagnosed on echocardiography, in 52 patients (Group A)—low PH probability. Most pronounced differences (p ≤ 0.0005) between groups B and A concerned: age, 6MWD, room air oxygen saturation at 6 min, DLCO and TLC/DLCO index (57.6 vs 43.8 years; 478 vs 583 m; 89.1% vs 93.4%; 54.8% predicted vs 70.5% predicted and 1.86 vs 1.44; respectively). Univariate analysis showed four-fold increased probability of PH when TLC/DLCO exceeded 1.67. A scoring system incorporating age, TLC/DLCO index, 6MWD and room air oxygen saturation at 6 min provided high diagnostic utility, AUC 0.867 (95% CI 0.792–0.867). Conclusion: ILD patients with TLC/DLCO index > 1.67 have a high likelihood of PH and should undergo further evaluation. The composite model of PH prediction, including age, 6-min walk test and TLC/DLCO was highly specific for recognition of PH on echocardiography.

24 September 2013 in Polish Archives of Internal Medicine
Verified
Journal Article
Open access
ERElżbieta Radzikowska
Elżbieta Radzikowska
PJPaulina Jaguś
Paulina Jaguś
ASAgnieszka Skoczylas
Agnieszka Skoczylas
MSMałgorzata Sobiecka
Małgorzata Sobiecka
JCJoanna Chorostowska‑Wynimko
Joanna Chorostowska‑Wynimko
KRKazimierz Roszkowski‑Śliż
Kazimierz Roszkowski‑Śliż
Polycystic lung diseases (PLDs) include numerous rare diseases including lymphangioleiomyomatosis (LAM), pulmonary Langerhans cell histiocytosis (PLCH), and lymphocytic interstitial pneumonia. In these cases, diagnosis is based on a histological examination of open lung biopsy samples; however, it is not always possible to perform this procedure. Serum markers characteristic for a given entity are still being sought. The aim of the study was to determine the usefulness of assessing serum vascular endothelial growth factor D (VEGF‑D) concentration in the differential diagnosis of LAM and other PLDs (OPLDs). Serum VEGF‑D levels were measured by an enzyme‑linked immunosorbent assay in 75 patients with PLDs including 29 women with LAM and 46 patients with OPLDs (28 women and 18 men). Serum VEGF‑D levels were significantly higher in patients with LAM (median, 1557 pg/ml; interquartile range [IQR], 636-2593 pg/ml) than in all patients with OPLDs (median, 292 pg/ml; IQR, 233-405 pg/ml, P <0.0001) or than in women with OPLDs (median, 344 pg/ml; IQR, 243-452 pg/ml, P <0.0001). The serum VEGF‑D level exceeding 468 pg/ml identified LAM patients with the specificity of 90% and sensitivity of 87% (area under the curve of 0.908; 95% confidence interval, 0.820-0.996). In none of the patients with OPLDs serum VEGF‑D concentrations exceeded 800 pg/ml. An increased serum VEGF‑D level is a highly specific biomarker useful in a differential diagnosis of LAM and OPLDs.

Verified
Journal Article
Open access
MSMonika Szturmowicz
Monika Szturmowicz
AKAneta Kacprzak
Aneta Kacprzak
Monika FranczukMonika Franczuk
Monika Franczuk
BBBarbara Burakowska
Barbara Burakowska
Marcin Kurzyna, MD, PhD, FESCMarcin Kurzyna, MD, PhD, FESC
Marcin Kurzyna, MD, PhD, FESC
Adam TorbickiAdam Torbicki
Adam Torbicki
Introduction: Decreased diffusing capacity of the lung for carbon monoxide (DLCO) is observed in some idiopathic pulmonary arterial hypertension (IPAH) patients, but its clinical significance is uncertain. We aimed to assess clinical correlates and prognostic significance of low DLCO in IPAH patients. Material and methods: In the group of 65 IPAH patients the cut off value for low DLCO was set up based on histogram as < 55% of predicted value. Demographic data, exercise capacity, lung function tests, hemodynamic parameters and survival of the patients were compared depending on DLCO value. Results: Low DLCO was found in 18% of the patients, and it was associated with male sex, older age, worse functional status and exercise capacity, and higher prevalence of coronary artery disease. Low DLCO carried a 4-fold increase of death risk in 5-year perspective. Conclusions: Low DLCO was a marker of worse functional capacity and increased risk of death in studied IPAH patients.

14 April 2025 in Rheumatology
Verified
Journal Article
Open access
Kamil KoszelaKamil Koszela
Kamil Koszela
MWMarta Woldanska-Okonska
Marta Woldanska-Okonska
ASAgnieszka Skoczylas
Agnieszka Skoczylas
Michał SłupińskiMichał Słupiński
Michał Słupiński
RGRobert Gasik
Robert Gasik
Objectives: Thoracic spine pain syndrome is far less common than lumbosacral or cervical pain. This pathology is often caused by work-related overload, especially sedentary work, lack of regular sport activities, and adopting incorrect postures. Thoracic spine pain may result, for instance, from degenerative joint lesions. In consequence, there is a reflex contraction of the soft, paraspinal tissues (muscles, fascia, ligaments). In this case, one of the treatment methods is spinal mesotherapy. The purpose of the present research was to evaluate the effectiveness and safety of thoracic spinal mesotherapy with collagen type I vs. lignocaine.Material and methods: A retrospective analysis of the results of the treatment of patients with chronic thoracic back pain syndrome using mesotherapy was performed. A total of 130 patients (49 men and 81 women; mean age: 49 ±9 years) were divided into 2 groups: group A (n = 65), treated with collagen type I, and group B (n = 65), treated with lignocaine 1%. Mesotherapy was performed weekly over 5 weeks. Patients were assessed using the Visual Analogue Scale (VAS) and Laitinen scales before the therapy, after the therapy, and after a 3-month follow-up visit.Results: A statistically significant improvement was observed after the use of thoracic spinal mesotherapy both with collagen type I and lignocaine, on the VAS and Laitinen scales, with the collagen treatment having better results at the 3-month follow-up visit. No adverse effects were observed after the procedures.Conclusions: Spinal mesotherapy is an effective and safe method of treating chronic thoracic back pain syndrome using collagen type I and lignocaine. However, in an average observation, collagen mesotherapy seems to be more effective.